Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction

X
Trial Profile

A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril; Valsartan
  • Indications Chronic heart failure; Heart failure
  • Focus Therapeutic Use
  • Acronyms PARALLAX
  • Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
  • Most Recent Events

    • 29 Aug 2022 Results of post-hoc analysis assessing the impact of sacubitril/valsartan on this endpoint in comparison to standard medical therapy, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 16 Nov 2021 Primary endpoint has not been met (Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24) , according to Results published in the JAMA: the Journal of the American Medical Association
    • 16 Nov 2021 Amendment 2: This amendment expanded EF inclusion criteria from current greater or equal to 45percent to greater than 40percent in order to ensure that LCZ696 clinical development program will cover full EF spectrum. The amendment also included a strategy for multiplicity testing of primary and secondary efficacy endpoints.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top